tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

RARE Stock Latest News

Ultragenyx Gains FDA Priority Review for DTX401 Therapy
Company AnnouncementsUltragenyx Gains FDA Priority Review for DTX401 Therapy
17h ago
8K
RARE
Ultragenyx announces U.S. FDA accepted for review BLA for DTX401 AAV
PremiumThe Fly
Ultragenyx announces U.S. FDA accepted for review BLA for DTX401 AAV
18h ago
RARE
Ultragenyx price target lowered to $34 from $37 at Evercore ISI
PremiumThe Fly
Ultragenyx price target lowered to $34 from $37 at Evercore ISI
6d ago
RARE
Ultragenyx price target lowered to $79 from $128 at Canaccord
PremiumThe Fly
Ultragenyx price target lowered to $79 from $128 at Canaccord
6d ago
RARE
Ultragenyx price target lowered to $37 from $39 at Evercore ISI
PremiumThe Fly
Ultragenyx price target lowered to $37 from $39 at Evercore ISI
7d ago
RARE
Ultragenyx price target lowered to $50 from $60 at H.C. Wainwright
PremiumThe FlyUltragenyx price target lowered to $50 from $60 at H.C. Wainwright
7d ago
RARE
Ultragenyx price target lowered to $45 from $50 at Citi
Premium
The Fly
Ultragenyx price target lowered to $45 from $50 at Citi
8d ago
RARE
Ultragenyx Earnings Call Balances Growth With Risk
Premium
Company Announcements
Ultragenyx Earnings Call Balances Growth With Risk
10d ago
RARE
Ultragenyx Pharmaceutical Faces Lawsuit Following Clinical Trial Disclosures
PremiumClass Action
Ultragenyx Pharmaceutical Faces Lawsuit Following Clinical Trial Disclosures
11d ago
RARE
Ultragenyx price target lowered to $49 from $75 at TD Cowen
PremiumThe Fly
Ultragenyx price target lowered to $49 from $75 at TD Cowen
11d ago
RARE
Ultragenyx price target lowered to $61 from $71 at Goldman Sachs
PremiumThe Fly
Ultragenyx price target lowered to $61 from $71 at Goldman Sachs
11d ago
RARE
Ultragenyx price target lowered to $40 from $47 at Baird
PremiumThe Fly
Ultragenyx price target lowered to $40 from $47 at Baird
11d ago
RARE
Ultragenyx Launches Restructuring Plan to Cut Costs
PremiumCompany AnnouncementsUltragenyx Launches Restructuring Plan to Cut Costs
11d ago
8K
RARE
Ultragenyx reports Q4 EPS ($1.29), consensus ($1.17)
Premium
The Fly
Ultragenyx reports Q4 EPS ($1.29), consensus ($1.17)
11d ago
RARE
Ultragenyx sees FY26 revenue $730M-$760M, consensus $790.67M
Premium
The Fly
Ultragenyx sees FY26 revenue $730M-$760M, consensus $790.67M
11d ago
RARE
RARE Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
RARE Upcoming Earnings Report: What to Expect?
14d ago
RARE
Ultragenyx: UX111 Progress, Regulatory De-Risking, and Pipeline Catalysts Support Attractive Risk/Reward and Buy Rating
PremiumRatings
Ultragenyx: UX111 Progress, Regulatory De-Risking, and Pipeline Catalysts Support Attractive Risk/Reward and Buy Rating
18d ago
RARE
Ultragenyx Highlights New UX111 Data in FDA Resubmission
PremiumCompany Announcements
Ultragenyx Highlights New UX111 Data in FDA Resubmission
21d ago
8K
RARE
Ultragenyx announces long-term data from studies evaluating UX111
PremiumThe Fly
Ultragenyx announces long-term data from studies evaluating UX111
21d ago
RARE
Ultragenyx: Advancing Rare Disease Pipeline, Key 2026–2027 Catalysts, and Path to Profitability Support Buy Rating
PremiumRatingsUltragenyx: Advancing Rare Disease Pipeline, Key 2026–2027 Catalysts, and Path to Profitability Support Buy Rating
21d ago
RARE
Ultragenyx Resubmits UX111 Gene Therapy for FDA Review
Premium
Company Announcements
Ultragenyx Resubmits UX111 Gene Therapy for FDA Review
25d ago
8K
RARE
Ultragenyx resubmits BLA for UX111 gene therapy with FDA
Premium
The Fly
Ultragenyx resubmits BLA for UX111 gene therapy with FDA
25d ago
RARE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >